Based in Seattle, Washington, Omeros Corporation is a leading biopharmaceutical company committed to discovering, developing, and commercializing innovative small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, and various disorders. The company is publicly traded on the NASDAQ under the ticker symbol "OMER."
Established in 1994 by Dr. Gregory A. Demopulos, Omeros has been at the forefront of the biotech industry for over two decades. The firm's groundbreaking research involves harnessing the power of the immune system and the biological pathways critical to its functioning. Central to this effort is Omeros' focus on the complement system, which is an essential component of the immune system that plays a pivotal role in inflammation and is implicated in a wide variety of autoimmune and inflammatory diseases.
The company's most successful drug on the market to date is Omidria, a solution used during cataract surgery or intraocular lens replacement to prevent pupil constriction and to reduce postoperative eye pain. Beyond Omidria, Omeros is bringing a broad pipeline of novel therapeutics to the fore. These developments are drawn from the company's proprietary PharmacoSurgery® platform, which is based on the concept of using currently marketed drugs in new ways during surgery to improve clinical outcomes.
Investors' interest in Omeros spiked after the company received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for its complement inhibitor, narsoplimab, for patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Meanwhile, the European Medicines Agency (EMA) has granted orphan drug designation and positive opinion on eligibility to apply for PRIME designation for narsoplimab, suggesting strong regulatory support.
Further, the company is also advancing its pipeline in other therapeutic areas, including addiction disorders, hematologic disorders, and multiple types of cancers.
As a pioneer in the biotech sector, Omeros Corp prioritizes transparency, ethics, and social responsibility. Its values of integrity, mutual respect, and teamwork are key drivers of its scientific innovation and success. Looking to the future, Omeros Corporation continues its path of discovery and innovation, aiming to provide better outcomes for patients and create value for its shareholders.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Cantor Fitzgerald upgraded Omeros Corp (NASDAQ: OMER) to Overweight with a $22 price target, believing its transplant drug Yartemlea could achieve higher sales than previously anticipated. The FDA-approved drug for TA-TMA generated $28.5 million in revenue in Q2 and received NTAP status for Medicare reimbursement, leading analysts to raise peak sales forecasts to $400 million. Despite positive physician feedback and strong patient adoption, the stock's current valuation does not fully reflect Yartemlea's potential.
This article analyzes Omeros Corporation (NASDAQ: OMER) focusing on volatility zones as tactical triggers for trading strategies. It highlights weak near and mid-term sentiment potentially challenging a long-term positive outlook, with an exceptional 76.2:1 risk-reward short setup identified. The analysis provides AI-generated institutional trading strategies tailored for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
The article provides a price-driven analysis for Omeros Corporation (NASDAQ: OMER), suggesting near-term neutral sentiment amidst mid and long-term strength. It outlines three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis, generated by AI models, also includes a multi-timeframe signal breakdown for support and resistance levels.
Omeros Corporation (OMER) has displayed a "golden cross" technical signal, where its 50-day simple moving average crossed above its 200-day simple moving average, suggesting a potential bullish breakout. The stock has rallied 70.4% in the past four weeks and holds a Zacks Rank of #3 (Hold). Combined with positive earnings outlooks and recent analyst upgrades, this technical indicator makes OMER a stock to watch.
Omeros Corporation (OMER) shares surged by 11.3% after the company announced a swing to net income for Q2 and H1 2026, repurchased shares, filed a shelf registration for ESOP-related stock, and expanded its board. This profitability shift and capital management, including the addition of a veteran investor to the Audit Committee, are reshaping its financial profile and governance. The company's future investment narrative now focuses on YARTEMLEA's commercial success and pipeline maturation, with analysts projecting significant revenue growth and a fair value of $33.00, suggesting a 71% upside.
Omeros (OMER) recently formed a hammer chart pattern, signaling a potential trend reversal as buying interest emerged against a downtrend. This technical indicator, combined with a 39% increase in consensus EPS estimates for the current year and a Zacks Rank #2 (Buy), suggests that the stock is poised for an upward movement. Analysts' positive revisions and the strong Zacks Rank indicate improving prospects and a likely outperformance compared to the market.
Omeros director Thomas J. Cable sold 15,000 common shares for $276,772.50 on August 20, 2026, at an average price of $18.45 per share. These transactions followed his exercise of two stock option tranches for the same number of shares at $2 and $3.93. As a result, his direct holdings in Omeros common shares decreased to 35,067.
Omeros Corp (OMER) Director Thomas Cable sold 15,000 shares of the company on August 20, 2026, for a total of $276,750, bringing his direct ownership to 35,067 shares. This sale is part of a year-long trend of insider selling with no insider purchases, which may be a cautionary signal for investors. The company's valuation metrics, including a P/E ratio of 15.05, suggest it may be trading at a discount compared to its industry peers but is more expensive relative to its own historical earnings.
Omeros Director Thomas Cable sold 15,000 shares of OMER stock for $276,750, reducing his stake by nearly 30%. The biopharmaceutical company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Omeros currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $38.00.
Wall Street analysts project a significant upside for Omeros (OMER), with a mean price target of $43.67, suggesting a 222.8% rally from its current price of $13.53. This optimistic outlook is further supported by positive earnings estimate revisions and a Zacks Rank #1 (Strong Buy) rating for the stock. However, the article cautions investors against relying solely on price targets due to potential biases and emphasizes the importance of considering other factors like earnings estimate trends.